venBio Partners
venBio is a venture investment firm founded in 2011 that focuses on life sciences and novel therapeutics for unmet medical needs. The firm invests through venture funds (reported aggregate committed capital ~ $2.0 billion) and partners with management teams to advance clinical and development plans, regulatory strategy, IP, and manufacturing with the explicit objective of creating companies positioned for clinical and commercial value.
venBio Partners
San Francisco, California, United States, North America
Services
Venture funding
Equity investments through venBio venture funds (current fifth fund ~ $528M committed).
Clinical development and trial strategy
Hands-on support for clinical trial design, endpoints, powering, indication selection and regulatory considerations to optimize development programs.
Regulatory strategy and acquisition positioning
Guidance and involvement to prepare companies for interactions with regulatory authorities and potential acquirers, including regulatory and commercial readiness.
Intellectual property and CMC support
Assistance and oversight related to intellectual property strategy and chemistry, manufacturing and controls (CMC) considerations.
Network and business development
Access to industry relationships and potential acquisition partners; facilitation of business development opportunities.
Venture funding
Equity investments through venBio venture funds (current fifth fund ~ $528M committed).
Clinical development and trial strategy
Hands-on support for clinical trial design, endpoints, powering, indication selection and regulatory considerations to optimize development programs.
Regulatory strategy and acquisition positioning
Guidance and involvement to prepare companies for interactions with regulatory authorities and potential acquirers, including regulatory and commercial readiness.
Intellectual property and CMC support
Assistance and oversight related to intellectual property strategy and chemistry, manufacturing and controls (CMC) considerations.
Network and business development
Access to industry relationships and potential acquisition partners; facilitation of business development opportunities.
Portfolio
#Pharmaceuticals / biotech
Announced AACR presentations (2025); develops radiopharmaceutical pipeline.
#Radiopharmaceuticals / oncology
#Pharmaceuticals / biotech
#Biotechnology
NASDAQ: AKRO; published Phase 2b SYMMETRY trial in NEJM (May 9, 2025).
#Metabolic / rare diseases
#Pharmaceuticals / biotech
Announced AACR presentations (2025); develops radiopharmaceutical pipeline.
#Radiopharmaceuticals / oncology
#Pharmaceuticals / biotech
#Biotechnology
NASDAQ: AKRO; published Phase 2b SYMMETRY trial in NEJM (May 9, 2025).
#Metabolic / rare diseases